Producer Cell Line for GMP Viral Vector Packaging
This is a contract result notice, not an open opportunity. Details from the official award data.
The procurement contact named on the official notice.
The Clinical Biotechnology Centre (CBC) has recently validated a GMP-compliant recombinant adeno‑associated viral vector (rAAV) manufacturing platform process to support UK academic clients in transitioning their gene therapy programmes from research into human clinical trials.
The work took over four years of intensive effort, including initial process development, iterative process optimisation and scale‑up to ensure suitability for GMP technology transfer.
Critical starting and raw materials were selected and approved for use on the platform, as well as determining the optimal process parameters to ensure consistent performance.
The validated platform process is now installed within the CBC’s GMP clean room viral vector manufacturing suites.
As rAAV manufacturing is inherently complex, technically demanding, and highly sensitive to changes in process conditions, any modification to the validated platform carries considerable risk to the quality of the products being manufactured.
Even minor changes could have a significant impact to disrupt platform performance that would require months of expensive re‑optimisation and re‑validation activities, which would present unacceptable operational and business risks.
What the supplier must deliver
The Clinical Biotechnology Centre (CBC) has recently
The Clinical Biotechnology Centre (CBC) has recently validated a GMP-compliant recombinant adeno‑associated viral vector (rAAV) manufacturing platform process to support UK academic clients in transitioning their gene therapy programmes from research into human clinical trials.
The work took over four years
The work took over four years of intensive effort, including initial process development, iterative process optimisation and scale‑up to ensure suitability for GMP technology transfer.
Critical starting and raw materials were selected
Critical starting and raw materials were selected and approved for use on the platform, as well as determining the optimal process parameters to ensure consistent performance.
Derived from the notice text — always confirm against the original documents.
Make the case to bid
Reveal who to approach at NHS Blood and Transplant, and generate a go-to-market strategy from their news, accounts and people.
Ask me about this tender, the buyer, who wins their work, or whether you should bid.
- OCID
- ocds-h6vhtk-0680f1
- Stage
- award · Awarded
- Source
- Find a Tender
- Buyer ref
- 039802-2026
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
NHS Blood and Transplant’s tender network
Assembling the network…